To determine the potential role of complement as an antitumor mechanism in HER2 mAb therapies, we first assessed the direct activation of complement in vitro by trastuzumab, pertuzumab, or their combination against HER2+ tumor cells. This evidence concerns the gene ERBB2 and neoplasm.